475 related articles for article (PubMed ID: 15653660)
1. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
Sharkey RM; Goldenberg DM
J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
[TBL] [Abstract][Full Text] [Related]
2. Advances in cancer therapy with radiolabeled monoclonal antibodies.
Goldenberg DM; Sharkey RM
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):248-64. PubMed ID: 17043623
[TBL] [Abstract][Full Text] [Related]
3. Current status of therapy of solid tumors.
Jhanwar YS; Divgi C
J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled antibodies (mAbs).
DeNardo GL
Semin Nucl Med; 2005 Jul; 35(3):202-11. PubMed ID: 16098294
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based targeted radiation to pediatric tumors.
Modak S; Cheung NK
J Nucl Med; 2005 Jan; 46 Suppl 1():157S-63S. PubMed ID: 15653664
[TBL] [Abstract][Full Text] [Related]
6. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
7. The promise of targeted {alpha}-particle therapy.
Mulford DA; Scheinberg DA; Jurcic JG
J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
Reilly RM
J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
[No Abstract] [Full Text] [Related]
9. Current status and perspectives in alpha radioimmunotherapy.
Chérel M; Davodeau F; Kraeber-Bodéré F; Chatal JF
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):322-9. PubMed ID: 17043629
[TBL] [Abstract][Full Text] [Related]
10. Current status of therapy of solid tumors: brain tumor therapy.
Zalutsky MR
J Nucl Med; 2005 Jan; 46 Suppl 1():151S-6S. PubMed ID: 15653663
[TBL] [Abstract][Full Text] [Related]
11. [Radiolabeled antibodies for cancer treatment].
Barbet J; Chatal JF; Kraeber-Bodéré F
Med Sci (Paris); 2009 Dec; 25(12):1039-45. PubMed ID: 20035676
[TBL] [Abstract][Full Text] [Related]
12. Cancer radioimmunotherapy.
Sharkey RM; Goldenberg DM
Immunotherapy; 2011 Mar; 3(3):349-70. PubMed ID: 21395378
[TBL] [Abstract][Full Text] [Related]
13. Treatment of infection with radiolabeled antibodies.
Dadachova E; Casadevall A
Q J Nucl Med Mol Imaging; 2006 Sep; 50(3):193-204. PubMed ID: 16868533
[TBL] [Abstract][Full Text] [Related]
14. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.
Sharkey RM; Goldenberg DM
Cancer Invest; 2006 Feb; 24(1):82-97. PubMed ID: 16466997
[TBL] [Abstract][Full Text] [Related]
15. A pragmatic perspective on molecular targeted radionuclide therapy.
Larson SM; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():1S-3S. PubMed ID: 15653645
[No Abstract] [Full Text] [Related]
16. Targeted radionuclide therapy for solid tumors: an overview.
DeNardo SJ; Denardo GL
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S89-95. PubMed ID: 16979448
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy and colorectal cancer.
Koppe MJ; Bleichrodt RP; Oyen WJ; Boerman OC
Br J Surg; 2005 Mar; 92(3):264-76. PubMed ID: 15739250
[TBL] [Abstract][Full Text] [Related]
18. Status of radioimmunotherapy in the new millennium.
Imam SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
[TBL] [Abstract][Full Text] [Related]
19. Current status of cancer therapy with radiolabeled monoclonal antibody.
Oriuchi N; Higuchi T; Hanaoka H; Iida Y; Endo K
Ann Nucl Med; 2005 Jul; 19(5):355-65. PubMed ID: 16164191
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of prostate cancer.
Smith-Jones PM
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]